Tagged with R&D

Holland Pivot Park in Oss, the Netherlands, aims at becoming an inspiring campus for open innovation in life sciences. The CEO discusses the unique assets the park offers to companies and calls for an increased collaboration among private industry, academia, and government to enhance the country’s global competitiveness. You took over…

Holland Thijs De Kleer, Managing Director, Saco de Visser, Director Cluster Development, discuss recent developments at the Netherlands largest science park and how Leiden has positioned itself as a leader in early stages of development, which creates a great environment to foster innovation. Leiden lies at the center of the Dutch…

research AM Pharma is developing an innovative treatment for acute kidney injury, and minority investor Pfizer recently acquired the option to purchase the firms remaining equity upon the completion of a phase II clinical trial. How competitive do you feel Dutch life sciences in the academic setting are amongst your other…

Turkey Recep Altekin, the general manager of MT Sağlik – market leader in Turkey for blood glucose monitoring systems and diabetes test strips by volume – tells PharmaBoardroom about his company’s impact on the Turkish medical device industry, and the value-added solutions that come packaged under the MT umbrella. Can you break…

Chiesi Chiesi is preparing to market two first in class products: the first approved stem cell treatment in Europe, and the first approved gene-therapy, developed in the Netherlands by partner UniQure. General Manager Nether Maurits Huigen discusses the challenges his affiliate is facing to bringing these pioneering products to market, along…

manufacturing The chancellor of the Medical Sciences Campus of the University of Puerto Rico discusses the medical R&D projects the university is currently involved in, the fields in which the island has the most potential, and how the institution is tailoring its academic offer to suit the local needs of the…

Puerto Rico Verónica Cruz, PhD, executive vice president and COO of Puerto Rican consultancy ReComS Group, discusses the need to bring investments in the life science industry back to Puerto Rico while focusing on the country’s manufacturing strengths as a competitive advantage. What are the main challenges which ReComS is facing? Today…

strategic levels Umut Gökalp, managing director of Japan’s Sysmex in Turkey – a company specialising in in-vitro diagnostics – evaluates their approach to developing business opportunities in the Turkish medical device sector. He also describes how the company’s new reagent facility in Germany will help bolster it domestically and regionally. Can you tell us…

investment The new government of Mauritius has chosen pharmaceuticals, healthcare and life sciences as priorities for the country’s innovation economy. Pharmaboardroom spoke with Ameenah Gurib Fakim, president of the Republic of Mauritius, who outlined her country’s strengths, and the challenge of replacing the country’s conventional “sun and sand” image with life sciences. Mauritius’ successful growth…

R&D Today’s Thai pharmaceutical market requires companies to adapt new leadership styles and carry new medicines in order to adjust to the needs of patients and clients. T. Man Pharma’s motto: “committed, innovative and developing quality pharmaceutical products to meet international standards” is what the director of sales and marketing, and…

locals Tuğçe Koç describes the company’s initial aspirations in targeting the higher value-added therapeutic area of oncology and the type of market opportunities that are present domestically and internationally. With over 25 years of experience, Onko Koçsel has established a strong foothold in the Turkish pharmaceutical industry—first with the introduction of…

basic research The Thailand Center of Excellence for Life Sciences (TCELS) CEO shares his ambitions to make Thailand a place for innovative business practices, the organization’s role in promoting and supporting research and the unique role TCELS plays in creating a regulatory frameworks for the life sciences industry. What special experiences led…